Stay updated with breaking news from Daniel Mikol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NervGen Pharma Corp. , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief...
NervGen Pharma Corp. , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, reported its financial and operational results for the...
Phase 1b/2a trial expected to commence in Q3 2023First readout anticipated in 2024Vancouver, British Columbia--(Newsfile Corp. - April 13, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen"
Completed NVG-291 dosing of subjects in Phase 1 clinical trialPhase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury planned to start in Q3 2023NVG-291 has been demonstrated in preclinical
NervGen Preparing for Upcoming Phase 1b Clinical Trial in Alzheimer's Disease Vancouver, British Columbia--(Newsfile Corp. - June 10, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen"